Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2019

16.10.2018 | Epidemiology

Predictors of time to death after distant recurrence in breast cancer patients

verfasst von: Victoria Sopik, Ping Sun, Steven A. Narod

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

After experiencing a distant recurrence, breast cancer patients have a poor prognosis; fewer than 5% survive for ten or more years. However, the time to death is highly variable, ranging from a few months to many years. The purpose of this study is to identify, in a large hospital-based series of patients with early-stage breast cancer, factors which predict survival after distant recurrence.

Methods

We studied a cohort of 2312 women diagnosed with invasive breast cancer at Women’s College Hospital between 1987 and 2000 (stages I–III). For each patient, we abstracted information on age at diagnosis, the initial presentation of the cancer (tumour size, lymph node status, tumour grade, ER status, PR status, HER2 status), treatment (surgery, radiotherapy, chemotherapy, hormone therapy), the dates of all tumour recurrences (local, regional, distant) and the dates and causes of death. The Cox proportional hazards model was used to estimate the univariate and multivariate hazard ratios for death from breast cancer following distant recurrence associated with the various tumour features.

Results

After a mean follow-up of 12.8 years from diagnosis, 523 distant recurrences were recorded among women in the cohort (23% of 2312) and 604 women (26%) died of breast cancer. For the 484 women who had a distant recurrence on record and died of breast cancer, the mean time from distant recurrence to death was 2.0 years (range 0–11.9 years). In a multivariate analysis, only two factors were significantly associated with time to death after distant recurrence: ER status (positive vs. negative, HR 0.56; 95% CI 0.43–0.71; p < 0.0001) and tumour grade (high vs. low, HR 1.87; 95% CI 1.16–3.01; p = 0.01). Among ER-negative patients (N = 175), high tumour grade and a short time from diagnosis to distant recurrence were associated with a rapid time to death. Among ER-positive patients (N = 336), there was no significant independent predictor of time from recurrence to death.

Conclusions

Among ER-negative breast cancer patients, the time to death after distant recurrence was predictable to some extent; women with a short time from diagnosis to recurrence and/or with high-grade tumours were more likely to succumb to breast cancer within 3 years. Among ER-positive breast cancer patients who experience a distant recurrence, the time to death varies substantially and between patients could not be predicted by tumour factors or treatment. This suggests that for ER-positive patients, the factors that determine the time from diagnosis to distant recurrence do not predict the course of the cancer post-recurrence.
Literatur
1.
Zurück zum Zitat Schairer C, Mink PJ, Carroll L, Devesa SS (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96:1311–1321CrossRefPubMed Schairer C, Mink PJ, Carroll L, Devesa SS (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96:1311–1321CrossRefPubMed
3.
Zurück zum Zitat Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434CrossRefPubMed Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434CrossRefPubMed
4.
Zurück zum Zitat Pan H, Gray R, Braybrooke J et al (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377:1836–1846CrossRefPubMedPubMedCentral Pan H, Gray R, Braybrooke J et al (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377:1836–1846CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Tevaarwerk AJ, Gray RJ, Schneider BP et al (2013) Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer 119:1140–1148CrossRefPubMed Tevaarwerk AJ, Gray RJ, Schneider BP et al (2013) Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer 119:1140–1148CrossRefPubMed
7.
Zurück zum Zitat Kwast AB, Voogd AC, Menke-Pluijmers MB et al (2014) Prognostic factors for survival in metastatic breast cancer by hormone receptor status. Breast Cancer Res Treat 145:503–511CrossRefPubMed Kwast AB, Voogd AC, Menke-Pluijmers MB et al (2014) Prognostic factors for survival in metastatic breast cancer by hormone receptor status. Breast Cancer Res Treat 145:503–511CrossRefPubMed
8.
Zurück zum Zitat Kuru B, Camlibel M, Dinc S, Gulcelik MA, Gonullu D, Alagol H (2008) Prognostic factors for survival in breast cancer patients who developed distant metastasis subsequent to definitive surgery. Singapore Med J 49:904–911PubMed Kuru B, Camlibel M, Dinc S, Gulcelik MA, Gonullu D, Alagol H (2008) Prognostic factors for survival in breast cancer patients who developed distant metastasis subsequent to definitive surgery. Singapore Med J 49:904–911PubMed
9.
Zurück zum Zitat Planchat E, Durando X, Abrial C et al (2011) Prognostic value of initial tumor parameters after metastatic relapse. Cancer Invest 29:635–643CrossRefPubMed Planchat E, Durando X, Abrial C et al (2011) Prognostic value of initial tumor parameters after metastatic relapse. Cancer Invest 29:635–643CrossRefPubMed
10.
Zurück zum Zitat Rogoz B, Houzé de l’Aulnoit A, Duhamel A, Houzé de l’Aulnoit D (2018) Thirty-year trends of survival and time-varying effects of prognostic factors in patients with metastatic breast cancer-a single institution experience. Clin Breast Cancer 18:246–253CrossRefPubMed Rogoz B, Houzé de l’Aulnoit A, Duhamel A, Houzé de l’Aulnoit D (2018) Thirty-year trends of survival and time-varying effects of prognostic factors in patients with metastatic breast cancer-a single institution experience. Clin Breast Cancer 18:246–253CrossRefPubMed
12.
Zurück zum Zitat Kim HJ, Ahn SG, Lee HM et al (2015) Metastasis-free interval is closely related to tumor characteristics and has prognostic value in breast cancer patients with distant relapse. J Breast Cancerm 18:371–377CrossRef Kim HJ, Ahn SG, Lee HM et al (2015) Metastasis-free interval is closely related to tumor characteristics and has prognostic value in breast cancer patients with distant relapse. J Breast Cancerm 18:371–377CrossRef
13.
Metadaten
Titel
Predictors of time to death after distant recurrence in breast cancer patients
verfasst von
Victoria Sopik
Ping Sun
Steven A. Narod
Publikationsdatum
16.10.2018
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-5002-9

Weitere Artikel der Ausgabe 2/2019

Breast Cancer Research and Treatment 2/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.